Genetic drivers in the natural history of chronic lymphocytic leukemia development as early as 16 years before diagnosisP. Martijn Kolijn, Anton W. Langerak, Florentin Späth et al.|Blood|2023Cited by 7
137 | IBRUTINIB ADDED TO MCL TREATMENT HAS STRONG IMPACT ON MRD RESPONSE AND DISEASE KINETICS: RESULTS FROM THE TRIANGLE TRIALMouhamad Khouja, Christiane Pott, Christa Homburg et al.|Hematological Oncology|2025Cited by 1
265 | IMPACT OF IGHV REPERTOIRE AFTER IBRUTINIB‐CONTAINING REGIMENS IN YOUNGER UNTREATED MCL PATIENTS: AN ANALYSIS OF THE TRIANGLE DATA EMBEDDED IN THE MULTIPLY PROJECTSimone Ragaini, Marco Ladetto, Riccardo Moia et al.|Hematological Oncology|2025Cited by 1
P601: GENETIC DRIVERS IN THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA DEVELOPMENT AS EARLY AS 16 YEARS BEFORE DIAGNOSISP. Martijn Kolijn, Anton W. Langerak, Florentin Späth et al.|HemaSphere|2023Cited by 0